Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's in stroke compound supply deal with Sygnis

Dr Reddy's signs an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient for stroke and other neurodegenrative disorders

Indian pharmaceutical company Dr Reddy's Laboratories has signed an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient used in the treatment of stroke and other neurodegenrative disorders.

The active ingredient is biological molecule AX200, which is being developed by Sygnis. The company successfully completed phase IIa clinical trials of the compound in September 2007, which demonstrated safety and efficacy in patients with acute stroke.

Sygnis plans to begin phase IIb trial in H2 2008. The study will be an efficacy trial in acute stroke. AX200 is the most advanced product in Sygnis' portfolio.

Cartikeya Reddy, head of biologics, at Dr Reddy's, said: "Our strategic decision to exclusively produce a biological molecule for a partner is a first in the history of Dr Reddy's and fits very well within our custom pharmaceutical services' business model. We are very optimistic that AX200 will continue to show real potential in the treatment of acute stroke with the potential to be used in the treatment of other degenerative neurological diseases."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...